Phenothiazin-5-ium, 3,7-bis(dimethylamino)-, chloride (1:1)

FDA’s June 2024 list of off-patent, off-exclusivity drugs sees rise in cancer, HIV treatments

This week PharmaCompass brings to you key highlights of the US Food and Drug Administration’s